All Stories

  1. Drug Delivery with Extracellular Vesicles: From Imagination to Innovation
  2. A head-to-head comparison of conjugation methods for VHHs: random maleimide-thiol coupling versus controlled click chemistry
  3. Development and characterization of liposomal formulation of bortezomib
  4. Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery
  5. Thermosensitive liposomes for triggered release of cytotoxic proteins
  6. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
  7. Nanomedicines for the treatment of hematological malignancies
  8. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety
  9. Nanomechanics of Extracellular Vesicles Reveals Vesiculation Pathways
  10. Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting
  11. Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles
  12. Squeezing for Life – Properties of Red Blood Cell Deformability
  13. Quantitative measurement of red cell surface protein expression reveals new biomarkers for hereditary spherocytosis
  14. State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery
  15. Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach
  16. Polymers and hydrogels for local nucleic acid delivery
  17. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology
  18. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis
  19. Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative
  20. Tumour-bound RNA-laden exosomes
  21. Microbubbles-Assisted Ultrasound Triggers the Release of Extracellular Vesicles
  22. Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles
  23. In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System
  24. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction
  25. Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy
  26. Polyphosphate nanoparticles on the platelet surface trigger contact system activation
  27. Clinical application of polymeric micelles for the treatment of cancer
  28. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – an ISEV position paper
  29. Interaction of Extracellular Vesicles with Endothelial Cells Under Physiological Flow Conditions
  30. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model
  31. ADDR editorial “Biologically-inspired drug delivery systems”
  32. Extracellular vesicles for drug delivery
  33. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment
  34. Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention
  35. Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro
  36. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells
  37. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
  38. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting
  39. Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency
  40. Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice
  41. An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs
  42. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
  43. Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π–Π Stacking Stabilized Polymeric Micelles
  44. Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics
  45. Mechanics of Extracellular Vesicles from Red Blood Cells
  46. Extracellular Vesicles: Potential Roles in Regenerative Medicine
  47. Extracellular vesicles as drug delivery systems: Lessons from the liposome field
  48. Intercalating quaternary nicotinamide-based poly(amido amine)s for gene delivery
  49. EVpedia: a community web portal for extracellular vesicles research
  50. 448 Exposure to EGFR inhibitors influences release of extracellular vesicles by tumor cells
  51. Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease
  52. Anginex lipoplexes for delivery of anti-angiogenic siRNA
  53. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma
  54. Hemocompatibility Assessment of two siRNA Nanocarrier Formulations
  55. Toward routine detection of extracellular vesicles in clinical samples
  56. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation
  57. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment
  58. Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles
  59. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles
  60. Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways
  61. Trends in polymeric delivery of nucleic acids to tumors
  62. Taxol®-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor®EL
  63. Strategies for triggered drug release from tumor targeted liposomes
  64. Red blood cell: barometer of cardiovascular health?
  65. Extracellular vesicles in the circulation: are erythrocyte microvesicles a confounder in the plasma haemoglobin assay?
  66. Oligonucleotides
  67. Red blood cell vesiculation in hereditary hemolytic anemia
  68. International Society for Extracellular Vesicles: Second Annual Meeting, 17–20 April 2013, Boston, MA (ISEV 2013)
  69. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells
  70. Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation
  71. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles
  72. 121 Tumor-targeted Nanobullets for Anti-cancer Combination Therapy
  73. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model
  74. Drug targeting systems for inflammatory disease: One for all, all for one
  75. 1043 Novel Anti-angiogenic MiRNAs Reduce in Vivo Tumor Growth in Mouse Models
  76. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery
  77. Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis
  78. Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis
  79. Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines
  80. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles
  81. Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α2β1 receptor
  82. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes
  83. Abstract 1112: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library
  84. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment
  85. Exosome mimetics: a novel class of drug delivery systems
  86. Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies
  87. Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics
  88. Polyplexes based on cationic polymers with strong nucleic acid binding properties
  89. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery
  90. Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding
  91. Abstract A12: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library
  92. Editorial [ Hot Topic:siRNA Based Approaches in Medicinal Chemistry and Drug Discovery (Guest Editor: Raymond M. Schiffelers )]
  93. Micro-Vesiculation and Disease, London, 13–14 September 2012
  94. Polymeric Carrier Systems for siRNA Delivery
  95. A role for activated endothelial cells in red blood cell clearance: implications for vasopathology
  96. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy
  97. Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression
  98. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: Comparison with stealth liposomes
  99. SiRNA delivery with functionalized carbon nanotubes
  100. Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors
  101. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes
  102. Physicochemical and Biological Evaluation of siRNA Polyplexes Based on PEGylated Poly(amido amine)s
  103. Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach
  104. Neovascular Age-Related Macular Degeneration
  105. Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer
  106. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity
  107. Gene silencing activity of siRNA polyplexes based on biodegradable polymers
  108. Optimization of poly(amido amine)s as vectors for siRNA delivery
  109. The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy
  110. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity
  111. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain
  112. Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids
  113. Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity
  114. Gene Silencing Activity of siRNA Polyplexes Based on Thiolated N , N , N -Trimethylated Chitosan
  115. Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis
  116. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation
  117. A method for quantifying cellular uptake of fluorescently labeled siRNA
  118. Poly(amido amine) copolymers derived from aminobutanol and ethylene diamine are excellent carriers for siRNA delivery
  119. Photochemical internalization (PCI)-mediated enhancement of gene silencing efficiency of polymethacrylates and N,N,N-trimethylated chitosan (TMC) based siRNA polyplexes
  120. Tumor vasculature as target for therapeutic intervention
  121. In Vivo Methods to Study Uptake of Nanoparticles into the Brain
  122. Liposomes targeting tumour stromal cells
  123. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin
  124. Downregulation of EGFR by a novel multivalent nanobody-liposome platform
  125. Abstract 5485: Modular nanotransporters: a chimeric multi-functional platform for drug deliveryin vivo
  126. Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability
  127. Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier
  128. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies
  129. Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
  130. Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
  131. Targeted Delivery of Anti-Inflammatory Agents to Tumors
  132. Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells
  133. Long circulating biodegradable polymeric micelles: Towards targeted drug delivery
  134. Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo
  135. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
  136. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice
  137. Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil
  138. L31 Thermosensitive and biodegradable polymeric micelles with transient stability for targeted drug delivery
  139. Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells
  140. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice
  141. Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue
  142. Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine
  143. Utility of Targeted Glucocorticoids in Cancer Therapy
  144. Hydrolysable core-crosslinked thermosensitive polymeric micelles: Synthesis, characterisation and in vivo studies
  145. Oligonucleotides
  146. Targeting the retinal microcirculation to treat diabetic sight problems
  147. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice
  148. Delivery of Nucleic Acids
  149. Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA
  150. Synthetic delivery systems for intravenous administration of nucleic acids
  151. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes
  152. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration
  153. Pharmaceutical Nanocarriers in Treatment and Imaging of Infection
  154. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice
  155. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy
  156. ICS-283: a system for targeted intravenous delivery of siRNA
  157. Silencing Proteins: Nanotechnological Approaches to Deliver siRNA for Cancer Therapy
  158. Targeted Delivery of siRNA
  159. Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer
  160. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis
  161. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
  162. Transporting silence: Design of carriers for siRNA to angiogenic endothelium
  163. Liposomal Targeting of Angiogenic Vasculature
  164. 318. Tumor Growth Inhibition from Tumor Targeted Delivery of Diphtheria Toxin Gene
  165. siRNA-mediated inhibition of angiogenesis
  166. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery
  167. Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice
  168. siRNA as a new drug: intellectual property
  169. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis
  170. Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections
  171. Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes
  172. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle
  173. Pharmaceutical Prospects for RNA Interference
  174. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
  175. Innovations in liposomal formulations for antimicrobial therapy
  176. Peptide-targeted PEG-liposomes in anti-angiogenic therapy
  177. Innovations in liposomal formulations for antimicrobial therapy
  178. Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses
  179. Endothelial Cells at Inflammatory Sites as Target for Therapeutic Intervention
  182. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
  183. Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin
  184. Activity of mammalian secreted phospholipase A2 from inflammatory peritoneal fluid towards PEG-liposomes. Early indications
  185. Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models
  186. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating
  187. Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes
  188. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics
  189. Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice
  190. Diagnostic and Therapeutic Targeting of Infectious and Inflammatory Diseases Using Sterically Stabilized Liposomes
  191. Quantitative Assessment of Aortic Atherosclerosis in APOE*3 Leiden Transgenic Mice and Its Relationship to Serum Cholesterol Exposure
  192. Lipid-Based Formulations for siRNA Delivery